BTMD - רווח נקי למניה (EPS TTM) Biote

The annual earnings per share dynamics of biote Corp. (BTMD) correlate with bioidentical hormone sales and therapy technologies. The current value of -0.09 describes the metric's current status amid franchise expansion and the introduction of nutraceuticals to drive margin growth. Business resilience is supported by extensive physician training and high loyalty among longevity experts.

For biote Corp. (BTMD), which focuses on hormone therapy and a conservative ESG approach, the change in TTM net income per share demonstrates the efficiency of its medical technology monetization. This metric is calculated by dividing the total annual net income by the number of shares outstanding, allowing investors to assess the actual return per share and compare fundamental business growth with sector market multiples.